- Home
- HL vs ARWR Comparison
HL vs ARWR Comparison
Compare HL & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HL | ARWR |
|---|---|---|
| Founded | 1891 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 12.4B |
| IPO Year | 2002 | 2009 |
Fundamental Metrics
Financial Performance| Metric | HL | ARWR |
|---|---|---|
| Price | $20.68 | $86.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $21.13 | ★ $83.40 |
| AVG Volume (30 Days) | ★ 35.8M | 1.0M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | ★ 716.67 | 99.80 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $645,957,000.00 | $16,142,321.00 |
| Revenue This Year | $4.92 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $140.70 | ★ N/A |
| Revenue Growth | ★ 45.63 | N/A |
| 52 Week Low | $10.38 | $27.10 |
| 52 Week High | $34.17 | $95.49 |
Technical Indicators
Market Signals| Indicator | HL | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 62.90 | 50.00 |
| Support Level | $20.47 | $82.70 |
| Resistance Level | $22.68 | $89.67 |
| Average True Range (ATR) | 1.03 | 2.64 |
| MACD | -0.03 | -0.65 |
| Stochastic Oscillator | 84.92 | 51.90 |
Price Performance
Historical ComparisonAbout HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.